Hematological VitroScreen
- Services
- Hematological VitroScreen

Industry-leading Hematologic Model Screening
Champions' Hematological VitroScreens offer a quick, cost-effective solution to test your therapeutics in an ex vivo hematologic assay evaluating efficacy and mechanisms of action in primary patient samples.
-
Largest primary hematological repository of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM) models
-
Well-characterized models featuring patient responses, clinical annotation, NGS data (WES and RNASeq), deep phenotyping using flow cytometry, proteomics, and phospho-proteomics datasets available in Lumin
Data-Driven Insights to Accelerate Your Hematologic Program

Hematological VitroScreen Endpoints










The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your immuno-oncology (IO) drugs in only 4 days using primary patient models.
In this study, we present an integrative analysis of multiple omic datasets coupled with phenotypic and therapeutic response profiles of Cytarabine from a cohort of primary Acute Myeloid Leukemia (AML) tumors, and Olaparib from a cohort of Patient-Derived Xenograft (PDX) models of ovarian cancer. These analyses, termed Pharmaco-Pheno- Multiomic (PPMO) Integration, established novel complex biomarker profiles that were used to accurately predict prospective therapeutic response profiles in cohorts of newly profiled AML and ovarian tumors.